Literature DB >> 16249321

American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: controlling tuberculosis in the United States.

.   

Abstract

During 1993-2003, incidence of tuberculosis (TB) in the United States decreased 44% and is now occurring at a historic low level (14,874 cases in 2003). The Advisory Council for the Elimination of Tuberculosis has called for a renewed commitment to eliminating TB in the United States, and the Institute of Medicine has published a detailed plan for achieving that goal. In this statement, the American Thoracic Society (ATS), Centers for Disease Control and Prevention (CDC), and the Infectious Diseases Society of America (IDSA) propose recommendations to improve the control and prevention of TB in the United States and to progress toward its elimination. This statement is one in a series issued periodically by the sponsoring organizations to guide the diagnosis, treatment, control, and prevention of TB. This statement supersedes the previous statement by ATS and CDC, which was also supported by IDSA and the American Academy of Pediatrics (AAP). This statement was drafted, after an evidence-based review of the subject, by a panel of representatives of the three sponsoring organizations. AAP, the National Tuberculosis Controllers Association, and the Canadian Thoracic Society were also represented on the panel. This statement integrates recent scientific advances with current epidemiologic data, other recent guidelines from this series, and other sources into a coherent and practical approach to the control of TB in the United States. Although drafted to apply to TB-control activities in the United States, this statement might be of use in other countries in which persons with TB generally have access to medical and public health services and resources necessary to make a precise diagnosis of the disease; achieve curative medical treatment; and otherwise provide substantial science-based protection of the population against TB. This statement is aimed at all persons who advocate, plan, and work at controlling and preventing TB in the United States, including persons who formulate public health policy and make decisions about allocation of resources for disease control and health maintenance and directors and staff members of state, county, and local public health agencies throughout the United States charged with control of TB. The audience also includes the full range of medical practitioners, organizations, and institutions involved in the health care of persons in the United States who are at risk for TB.

Entities:  

Mesh:

Year:  2005        PMID: 16249321     DOI: 10.1164/rccm.2508001

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  90 in total

1.  Detection of bacillus Galmette-Guérin (Mycobacterium bovis BCG) DNA in urine and blood specimens after intravesical immunotherapy for bladder carcinoma.

Authors:  Argyrios Siatelis; Dimitra P Houhoula; Joseph Papaparaskevas; Dimitrios Delakas; Athanassios Tsakris
Journal:  J Clin Microbiol       Date:  2011-01-26       Impact factor: 5.948

2.  Identifying the most infectious lesions in pulmonary tuberculosis by high-resolution multi-detector computed tomography.

Authors:  Jun Jun Yeh; Solomon Chih-Cheng Chen; Wen-Bao Teng; Chun-Hsiung Chou; Shih-Peng Hsieh; Tsung-Lung Lee; Ming-Ting Wu
Journal:  Eur Radiol       Date:  2010-04-30       Impact factor: 5.315

Review 3.  Recent advances in testing for latent TB.

Authors:  Neil W Schluger; Joseph Burzynski
Journal:  Chest       Date:  2010-12       Impact factor: 9.410

4.  Clinical characteristics and prognosis of nontuberculous mycobacterial lung disease with different radiographic patterns.

Authors:  Chin-Chung Shu; Chih-Hsin Lee; Chia-Lin Hsu; Jann-Tay Wang; Jann-Yuan Wang; Chong-Jen Yu; Li-Na Lee
Journal:  Lung       Date:  2011-09-29       Impact factor: 2.584

5.  Activism on rifapentine pricing: removing cost barriers to improve the uptake of tuberculosis research innovations.

Authors:  A DeLuca; M Frick; E Lessem; J Kanouse; D Wegener; L Ruiz Mingote
Journal:  Public Health Action       Date:  2014-12-21

6.  Acute Bilateral Tuberculous Pneumonia in a Patient with Systemic Lupus Erythematosus.

Authors:  Raghavendra Rao; Rama Bhat; Nitin Bhat; Savio D'Souza; Venkata Chenchaiah
Journal:  J Clin Diagn Res       Date:  2016-05-01

7.  Cost-effectiveness of Xpert® MTB/RIF for diagnosing pulmonary tuberculosis in the United States.

Authors:  H W Choi; K Miele; D Dowdy; M Shah
Journal:  Int J Tuberc Lung Dis       Date:  2013-10       Impact factor: 2.373

8.  Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults.

Authors:  Lionel A Mandell; Richard G Wunderink; Antonio Anzueto; John G Bartlett; G Douglas Campbell; Nathan C Dean; Scott F Dowell; Thomas M File; Daniel M Musher; Michael S Niederman; Antonio Torres; Cynthia G Whitney
Journal:  Clin Infect Dis       Date:  2007-03-01       Impact factor: 9.079

9.  Tuberculosis among Newly Arrived Immigrants and Refugees in the United States.

Authors:  Yecai Liu; Christina R Phares; Drew L Posey; Susan A Maloney; Kevin P Cain; Michelle S Weinberg; Kristine M Schmit; Nina Marano; Martin S Cetron
Journal:  Ann Am Thorac Soc       Date:  2020-11

10.  A case of tuberculosis in a pregnant woman and review of current literature.

Authors:  B C H Kwan; Y Yu; H Goldberg
Journal:  Obstet Med       Date:  2010-12-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.